ATRA - CIK 0001604464
The table below shows Atara Biotherapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$50.94M | -$68.72M | -$192.98M | -$270.43M | -$220.52M | -$180.76M |
| Capital expenditure | $0.00 | $246.00K | $1.22M | $4.19M | $10.58M | $4.51M |
| Investing cash flow | $18.15M | $8.62M | $123.87M | $202.96M | $22.26M | -$120.73M |
| Dividends paid | - | - | - | - | - |
Atara Biotherapeutics, Inc. reported operating cash flow of -$50.94M for fiscal year 2025. That is up 25.9% from -$68.72M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$60.02M (FY 2016) to -$50.94M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $16.10M | $59.28M | $2.01M | $53.08M | $103.94M | $427.57M |